熱門資訊> 正文
Gilead ' s Kite以3.5亿美元收购Interius BioTherapeutics
2025-08-21 21:26
- 吉利德科學(GILD) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Gilead Sciences' (NASDAQ:GILD) Kite unit will acquire Interius BioTherapeutics for $350M, strengthening its position with in vivo CAR therapeutics.
- Kite said that Interius' platform "enables the generation of CAR T-cells directly within the patient’s body and may offer a more durable and long-lasting therapeutic effect by inserting DNA into the patient's genome....Interius' innovative, off-the-shelf yet personalized approach is designed to be delivered via a single intravenous infusion, eliminating the need for preconditioning chemotherapy and complex cell processing."
- The deal is projected to reduce Gilead's GAAP and non-GAAP 2025 EPS by $0.23-$0.25.
- Interius' lead candidate, INT2104, is in phase 1 for b cell malignancies. It is designed to generate CAR-T and NK cells directly in vivo and via IV infusion without preconditioning chemotherapy.
More on Gilead Sciences
- From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave
- Gilead Sciences' Outperformance Means Overvalued
- Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript
- CVS Health reportedly excludes coverage for Gilead’s new HIV drug for now
- Earnings Scorecard: Wave of revenue wins for healthcare firms this week
推薦文章
財報前瞻 | 「外賣大戰」暫無贏家？阿里季度利潤料同樣下滑16%，高盛稱「閃購」虧損還未到達頂峰
英偉達Q2業績會實錄：GB300量產+Rubin全速推進，中國市場今年機遇規模達500億美元
攜程集團-S發佈第二季度業績 歸母淨利潤48.46億元同比增加26.43%
特朗普與美聯儲鬥爭升級！華爾街警告：美國陷入滯脹可能性升高
英偉達第二財季營收467.43億美元 淨利潤同比增長59%
美股機會日報 | 貝特森：美聯儲主席人選今秋揭曉！英偉達盤后將發財報
一圖看懂 | 利潤驟降！美團Q2淨利同比降低89%至14.9億元，大幅低於預期
8月27日外盤頭條：蘋果將於9月9日舉行發佈會 特朗普與美聯儲庫克鬥爭加劇 美國政府將入股目光投向國防產業
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
